Until 2002, Biogen had the MS market to itself because of a law that grants a temporarymonopoly to medicines for rare ailments, known in biotech as orphan diseases.
But the challenge has always lain with the first half of Lincoln's phrase--that is, how to stoke that genius through a system that both rewards the inventor with a temporary business monopoly and protects the competition that lies at the heart of the free-market system.